{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:15:34Z","timestamp":1773213334943,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T00:00:00Z","timestamp":1464825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T00:00:00Z","timestamp":1464825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite recent progress in the development of hepatitis C virus (HCV) inhibitors, cost-effective antiviral drugs, especially among the patients receiving liver transplantations, are still awaited. Schisandra is a traditional medicinal herb used to treat a range of liver disorders including hepatitis for thousands of years in China. To isolate the bioactive compounds of schisandra for the treatment of HCV infection, we screened a schisandra-extracts library and identified a tetracyclic triterpenoid, schizandronic acid (SZA), as a novel HCV entry inhibitor. Our findings suggested that SZA potently inhibited pan-HCV genotype entry into hepatoma cells and primary human hepatocytes without interfering virus binding on cell surface or internalization. However, virion-cell fusion process was impaired in the presence of SZA, along with the increased host membrane fluidity. We also found that SZA inhibited the spread of HCV to the neighboring cells, and combinations of SZA with interferon or telaprevir resulted in additive synergistic effect against HCV. Additionally, SZA diminished the establishment of HCV infection <jats:italic>in vivo<\/jats:italic>. The SZA target is different from conventional direct-acting antiviral agents, therefore, SZA is a potential therapeutic compound for the development of effective HCV entry inhibitors, especially for patients who need to prevent HCV reinfection during the course of liver transplantations.<\/jats:p>","DOI":"10.1038\/srep27268","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T10:16:18Z","timestamp":1464862578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human Hepatocytes"],"prefix":"10.1038","volume":"6","author":[{"given":"Xi-Jing","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Lian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Sheng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Lin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Zhe","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Tian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,2]]},"reference":[{"key":"BFsrep27268_CR1","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nm.3184","volume":"19","author":"DL Thomas","year":"2013","unstructured":"Thomas, D. L. Global control of hepatitis C: where challenge meets opportunity. Nature medicine 19, 850\u2013858, doi: 10.1038\/nm.3184 (2013).","journal-title":"Nature medicine"},{"key":"BFsrep27268_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1136\/gut.2005.076646","volume":"55","author":"MP Manns","year":"2006","unstructured":"Manns, M. P., Wedemeyer, H. & Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55, 1350\u20131359, doi: 10.1136\/gut.2005.076646 (2006).","journal-title":"Gut"},{"key":"BFsrep27268_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.2014.7085","volume":"312","author":"A Kohli","year":"2014","unstructured":"Kohli, A., Shaffer, A., Sherman, A. & Kottilil, S. Treatment of hepatitis C: a systematic review. Jama 312, 631\u2013640, doi: 10.1001\/jama.2014.7085 (2014).","journal-title":"Jama"},{"key":"BFsrep27268_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1126\/science.aad1302","volume":"349","author":"AL Cox","year":"2015","unstructured":"Cox, A. L. MEDICINE. Global control of hepatitis C virus. Science 349, 790\u2013791, doi: 10.1126\/science.aad1302 (2015).","journal-title":"Science"},{"key":"BFsrep27268_CR5","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.1128\/AAC.01209-12","volume":"56","author":"LA Pelosi","year":"2012","unstructured":"Pelosi, L. A., Voss, S., Liu, M., Gao, M. & Lemm, J. A. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrobial agents and chemotherapy 56, 5230\u20135239, doi: 10.1128\/AAC.01209-12 (2012).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep27268_CR6","first-page":"256","volume":"40","author":"D Gritsenko","year":"2015","unstructured":"Gritsenko, D. & Hughes, G. Ledipasvir\/Sofosbuvir (Harvoni): improving options for hepatitis C virus infection. P & T: a peer-reviewed journal for formulary management 40, 256\u2013276 (2015).","journal-title":"P & T: a peer-reviewed journal for formulary management"},{"key":"BFsrep27268_CR7","doi-asserted-by":"crossref","unstructured":"A 4-drug combination (Viekira Pak) for hepatitis C. Jama 313, 1857\u20131858, doi: 10.1001\/jama.2015.4562 (2015).","DOI":"10.1001\/jama.2015.4562"},{"key":"BFsrep27268_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/1756283X15587481","volume":"8","author":"BP Lam","year":"2015","unstructured":"Lam, B. P., Jeffers, T., Younoszai, Z., Fazel, Y. & Younossi, Z. M. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therapeutic advances in gastroenterology 8, 298\u2013312, doi: 10.1177\/1756283X15587481 (2015).","journal-title":"Therapeutic advances in gastroenterology"},{"key":"BFsrep27268_CR9","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1093\/infdis\/jis761","volume":"207","author":"DL Wyles","year":"2013","unstructured":"Wyles, D. L. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis 207 Suppl 1, S33\u201339, doi: 10.1093\/infdis\/jis761 (2013).","journal-title":"J Infect Dis"},{"key":"BFsrep27268_CR10","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1128\/JVI.02727-13","volume":"88","author":"GH Syed","year":"2014","unstructured":"Syed, G. H. et al. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol 88, 2519\u20132529, doi: 10.1128\/JVI.02727-13 (2014).","journal-title":"J Virol"},{"key":"BFsrep27268_CR11","doi-asserted-by":"publisher","first-page":"41003","DOI":"10.1074\/jbc.M302267200","volume":"278","author":"H Barth","year":"2003","unstructured":"Barth, H. et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278, 41003\u201341012, doi: 10.1074\/jbc.M302267200 (2003).","journal-title":"J Biol Chem"},{"key":"BFsrep27268_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.pmbts.2014.10.003","volume":"129","author":"F Douam","year":"2015","unstructured":"Douam, F., Lavillette, D. & Cosset, F. L. The mechanism of HCV entry into host cells. Prog Mol Biol Transl Sci 129, 63\u2013107, doi: 10.1016\/bs.pmbts.2014.10.003 (2015).","journal-title":"Prog Mol Biol Transl Sci"},{"key":"BFsrep27268_CR13","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1128\/JVI.00024-06","volume":"80","author":"E Blanchard","year":"2006","unstructured":"Blanchard, E. et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 80, 6964\u20136972, doi: 10.1128\/JVI.00024-06 (2006).","journal-title":"J Virol"},{"key":"BFsrep27268_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nm.2581","volume":"18","author":"B Sainz Jr.","year":"2012","unstructured":"Sainz, B. Jr. et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 18, 281\u2013285, doi: 10.1038\/nm.2581 (2012).","journal-title":"Nat Med"},{"key":"BFsrep27268_CR15","doi-asserted-by":"publisher","first-page":"10777","DOI":"10.1073\/pnas.1301764110","volume":"110","author":"DN Martin","year":"2013","unstructured":"Martin, D. N. & Uprichard, S. L. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci USA 110, 10777\u201310782, doi: 10.1073\/pnas.1301764110 (2013).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep27268_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nm.2341","volume":"17","author":"J Lupberger","year":"2011","unstructured":"Lupberger, J. et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nature medicine 17, 589\u2013595, doi: 10.1038\/nm.2341 (2011).","journal-title":"Nature medicine"},{"key":"BFsrep27268_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1478-3231.2006.01408.x","volume":"27","author":"HS Azzam","year":"2007","unstructured":"Azzam, H. S., Goertz, C., Fritts, M. & Jonas, W. B. Natural products and chronic hepatitis C virus. Liver Int 27, 17\u201325, doi: 10.1111\/j.1478-3231.2006.01408.x (2007).","journal-title":"Liver Int"},{"key":"BFsrep27268_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/01.mcg.0000174023.73472.29","volume":"39","author":"A Melhem","year":"2005","unstructured":"Melhem, A. et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol 39, 737\u2013742 (2005).","journal-title":"J Clin Gastroenterol"},{"key":"BFsrep27268_CR19","doi-asserted-by":"publisher","first-page":"11571","DOI":"10.1128\/JVI.01717-06","volume":"80","author":"L Meertens","year":"2006","unstructured":"Meertens, L., Bertaux, C. & Dragic, T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. Journal of virology 80, 11571\u201311578, doi: 10.1128\/JVI.01717-06 (2006).","journal-title":"Journal of virology"},{"key":"BFsrep27268_CR20","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1128\/JVI.01592-10","volume":"85","author":"CL Brimacombe","year":"2011","unstructured":"Brimacombe, C. L. et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. Journal of virology 85, 596\u2013605, doi: 10.1128\/JVI.01592-10 (2011).","journal-title":"Journal of virology"},{"key":"BFsrep27268_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nm1698","volume":"14","author":"M Law","year":"2008","unstructured":"Law, M. et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nature medicine 14, 25\u201327, doi: 10.1038\/nm1698 (2008).","journal-title":"Nature medicine"},{"key":"BFsrep27268_CR22","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/hep.24803","volume":"55","author":"N Calland","year":"2012","unstructured":"Calland, N. et al. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 55, 720\u2013729, doi: 10.1002\/hep.24803 (2012).","journal-title":"Hepatology"},{"key":"BFsrep27268_CR23","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.3748\/wjg.v20.i13.3457","volume":"20","author":"YZ Zhu","year":"2014","unstructured":"Zhu, Y. Z., Qian, X. J., Zhao, P. & Qi, Z. T. How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterol 20, 3457\u20133467, doi: 10.3748\/wjg.v20.i13.3457 (2014).","journal-title":"World J Gastroenterol"},{"key":"BFsrep27268_CR24","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/hep.24610","volume":"54","author":"S Ciesek","year":"2011","unstructured":"Ciesek, S. et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 54, 1947\u20131955, doi: 10.1002\/hep.24610 (2011).","journal-title":"Hepatology"},{"key":"BFsrep27268_CR25","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/hep.23445","volume":"51","author":"SE Krieger","year":"2010","unstructured":"Krieger, S. E. et al. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51, 1144\u20131157, doi: 10.1002\/hep.23445 (2010).","journal-title":"Hepatology"},{"key":"BFsrep27268_CR26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/hep.25685","volume":"56","author":"Y Si","year":"2012","unstructured":"Si, Y. et al. A human claudin-1-derived peptide inhibits hepatitis C virus entry. Hepatology 56, 507\u2013515, doi: 10.1002\/hep.25685 (2012).","journal-title":"Hepatology"},{"key":"BFsrep27268_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhep.2010.06.024","volume":"54","author":"AJ Syder","year":"2011","unstructured":"Syder, A. J. et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 54, 48\u201355, doi: 10.1016\/j.jhep.2010.06.024 (2011).","journal-title":"J Hepatol"},{"key":"BFsrep27268_CR28","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1002\/cbdv.200900173","volume":"7","author":"LJ Xu","year":"2010","unstructured":"Xu, L. J., Peng, Z. G., Chen, H. S., Wang, J. & Xiao, P. G. Bioactive triterpenoids from Kadsura heteroclita. Chem Biodivers 7, 2289\u20132295, doi: 10.1002\/cbdv.200900173 (2010).","journal-title":"Chem Biodivers"},{"key":"BFsrep27268_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature04083","volume":"436","author":"RS Brown","year":"2005","unstructured":"Brown, R. S. & Hepatitis, C. and liver transplantation. Nature 436, 973\u2013978, doi: 10.1038\/nature04083 (2005).","journal-title":"Nature"},{"key":"BFsrep27268_CR30","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.14233\/ajchem.2013.13176","volume":"25","author":"JL Du","year":"2013","unstructured":"Du, J. L. et al. Chemical and Biologically Active Constituents of Schisandra sphenanthera Rehd. et. Asian Journal of Chemistry 25, 2321\u20132322 (2013).","journal-title":"Asian Journal of Chemistry"},{"key":"BFsrep27268_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/hep.21016","volume":"43","author":"Y Nahmias","year":"2006","unstructured":"Nahmias, Y., Casali, M., Barbe, L., Berthiaume, F. & Yarmush, M. L. Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes. Hepatology 43, 257\u2013265, doi: 10.1002\/hep.21016 (2006).","journal-title":"Hepatology"},{"key":"BFsrep27268_CR32","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1128\/JVI.01190-09","volume":"84","author":"L Goueslain","year":"2010","unstructured":"Goueslain, L. et al. Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication. J Virol 84, 773\u2013787, doi: 10.1128\/JVI.01190-09 (2010).","journal-title":"J Virol"},{"key":"BFsrep27268_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1268","volume":"11","author":"T Wakita","year":"2005","unstructured":"Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature medicine 11, 791\u2013796, doi: 10.1038\/nm1268 (2005).","journal-title":"Nature medicine"},{"key":"BFsrep27268_CR34","doi-asserted-by":"publisher","first-page":"35631","DOI":"10.1074\/jbc.M112.382341","volume":"287","author":"M Guan","year":"2012","unstructured":"Guan, M. et al. Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J Biol Chem 287, 35631\u201335645, doi: 10.1074\/jbc.M112.382341 (2012).","journal-title":"J Biol Chem"},{"key":"BFsrep27268_CR35","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1128\/JVI.01818-10","volume":"85","author":"Y Tong","year":"2011","unstructured":"Tong, Y. et al. Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. Journal of virology 85, 2793\u20132802, doi: 10.1128\/JVI.01818-10 (2011).","journal-title":"Journal of virology"},{"key":"BFsrep27268_CR36","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1084\/jem.20021756","volume":"197","author":"B Bartosch","year":"2003","unstructured":"Bartosch, B., Dubuisson, J. & Cosset, F. L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. The Journal of experimental medicine 197, 633\u2013642 (2003).","journal-title":"The Journal of experimental medicine"},{"key":"BFsrep27268_CR37","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1038\/srep07242","volume":"4","author":"Y Chen","year":"2014","unstructured":"Chen, Y. et al. Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Scientific reports 4, 7242, doi: 10.1038\/srep07242 (2014).","journal-title":"Scientific reports"},{"key":"BFsrep27268_CR38","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.virol.2010.07.026","volume":"407","author":"A Sabahi","year":"2010","unstructured":"Sabahi, A. et al. The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology 407, 110\u2013119, doi: 10.1016\/j.virol.2010.07.026 (2010).","journal-title":"Virology"},{"key":"BFsrep27268_CR39","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1128\/AAC.02593-12","volume":"57","author":"AM Chamoun-Emanuelli","year":"2013","unstructured":"Chamoun-Emanuelli, A. M. et al. Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrobial agents and chemotherapy 57, 2571\u20132581, doi: 10.1128\/AAC.02593-12 (2013).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep27268_CR40","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/cr.2014.116","volume":"24","author":"J Chen","year":"2014","unstructured":"Chen, J. et al. Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized mice. Cell research 24, 1050\u20131066, doi: 10.1038\/cr.2014.116 (2014).","journal-title":"Cell research"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep27268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep27268","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep27268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T04:48:24Z","timestamp":1672894104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep27268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,6,28]]}},"alternative-id":["BFsrep27268"],"URL":"https:\/\/doi.org\/10.1038\/srep27268","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,2]]},"assertion":[{"value":"6 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27268"}}